Ayala Pharmaceuticals (ADXS) Competitors $0.03 -0.11 (-77.38%) As of 01:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. SLGL, RLYB, DRRX, JATT, BCTX, CING, MIRA, RVPH, PRPH, and MRKRShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Sol-Gel Technologies (SLGL), Rallybio (RLYB), DURECT (DRRX), JATT Acquisition (JATT), Briacell Therap (BCTX), Cingulate (CING), MIRA Pharmaceuticals (MIRA), Reviva Pharmaceuticals (RVPH), ProPhase Labs (PRPH), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Sol-Gel Technologies Rallybio DURECT JATT Acquisition Briacell Therap Cingulate MIRA Pharmaceuticals Reviva Pharmaceuticals ProPhase Labs Marker Therapeutics Ayala Pharmaceuticals (NASDAQ:ADXS) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Do analysts recommend ADXS or SLGL? Sol-Gel Technologies has a consensus price target of $40.00, suggesting a potential upside of 382.10%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ADXS or SLGL more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -107.78%. Ayala Pharmaceuticals' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Sol-Gel Technologies -107.78%-43.98%-35.28% Do institutionals and insiders have more ownership in ADXS or SLGL? 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer ADXS or SLGL? In the previous week, Sol-Gel Technologies had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 0 mentions for Ayala Pharmaceuticals. Sol-Gel Technologies' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Overall Sentiment Ayala Pharmaceuticals Neutral Sol-Gel Technologies Positive Which has preferable valuation and earnings, ADXS or SLGL? Sol-Gel Technologies has higher revenue and earnings than Ayala Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.44-$48.07M-$7.980.00Sol-Gel Technologies$11.54M2.01-$10.58M-$4.70-1.77 Which has more risk & volatility, ADXS or SLGL? Ayala Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. SummarySol-Gel Technologies beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42M$822.28M$5.53B$9.13BDividend YieldN/A4.84%5.06%4.01%P/E Ratio0.001.3728.5819.57Price / Sales0.44237.52372.6479.65Price / CashN/A17.6924.7227.51Price / Book-0.026.488.235.56Net Income-$48.07M-$23.77M$3.19B$252.37M7 Day PerformanceN/A1.50%5.46%3.11%1 Month PerformanceN/A1.21%9.39%11.74%1 Year PerformanceN/A3.74%30.48%17.41% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-77.4%N/A-29.9%$1.42M$3.24M0.0020Gap DownSLGLSol-Gel Technologies3.2074 of 5 stars$7.26-0.5%$40.00+451.3%-15.2%$20.24M$11.54M-1.5450Gap DownRLYBRallybio2.6475 of 5 stars$0.46+36.0%$10.00+2,059.8%-70.6%$19.64M$848K-0.4340High Trading VolumeDRRXDURECT1.2302 of 5 stars$0.63-1.6%N/A-54.7%$19.55M$1.86M-4.2080Positive NewsGap DownJATTJATT AcquisitionN/A$1.13+0.9%N/A-64.7%$19.49MN/A0.003High Trading VolumeBCTXBriacell Therap1.8972 of 5 stars$2.86-1.0%$32.00+1,018.9%-84.8%$19.32MN/A-0.348High Trading VolumeCINGCingulate3.0871 of 5 stars$4.46+0.9%$26.00+483.0%+911.6%$19.00MN/A-0.5320MIRAMIRA Pharmaceuticals2.2787 of 5 stars$1.11-3.9%$14.00+1,167.0%+117.2%$18.78MN/A-2.182RVPHReviva Pharmaceuticals3.2661 of 5 stars$0.39+5.8%$9.00+2,219.6%-68.5%$18.48MN/A-0.495Positive NewsGap UpPRPHProPhase Labs0.5408 of 5 stars$0.45+1.6%N/A-87.1%$18.44M$5.85M-0.35130Positive NewsMRKRMarker Therapeutics4.5207 of 5 stars$1.63+3.5%$13.17+710.3%-67.3%$18.38M$6.59M-1.2260 Related Companies and Tools Related Companies Sol-Gel Technologies Alternatives Rallybio Alternatives DURECT Alternatives JATT Acquisition Alternatives Briacell Therap Alternatives Cingulate Alternatives MIRA Pharmaceuticals Alternatives Reviva Pharmaceuticals Alternatives ProPhase Labs Alternatives Marker Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored“The Best Gold Investment You’ve Never Heard Of”Gold may be surging past $3,500 — but one rare class of stocks is leaving bullion in the dust. Gold royalti...Golden Portfolio | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
